Wall Street Breakfast Podcast: Moderna's Good News Goes Bad

Moderna shares plunged nearly 18% Thursday and were down 3% premarket despite positive Phase 3 results for its personalized melanoma vaccine developed with Merck. Crown Castle and American Tower rose sharply premarket after reports that SpaceX is seeking at least 80,000 U.S. cell sites and discussing opportunities with major infrastructure companies.

Analysis

Two distinct setups, neither yet supported by enough detail for an unconditional trade. For Moderna, the disconnect between favorable Phase 3 news and the sharp selloff suggests investors may be discounting the commercial value rather than the clinical headline: the key variables are effect size and durability, safety, regulatory path, and how economics are shared with Merck. Do not infer that the result is commercially decisive—or that the selloff is a bargain—without those details. Over 1–3 months, full trial data and company commentary on development and commercialization economics should matter more than the headline; a weak benefit-risk profile or limited economics for Moderna would falsify a recovery thesis.

For Crown Castle and American Tower, a reported search for cell sites creates upside only if it becomes signed, incremental tenancy with attractive returns. Early speculation can lift tower valuations before lease terms, build requirements, or timing are known. Over 6–18 months, actual deployments could support site demand, but substantial new infrastructure needs or a network design that bypasses existing tower assets would limit the benefit. Confirmation of executed agreements and identifiable incremental revenue is the catalyst; absent that, the premarket move is vulnerable to reversal. SpaceX’s reported discussions are not equivalent to committed leases.

Key Decisions for Investors

• MRNA: Avoid reflexively buying the post-result dip. Reassess after the full Phase 3 dataset and clarification of Merck/Moderna economics; a sustained favorable benefit-risk profile plus a credible regulatory path would support a staged long, while disappointing efficacy, safety, or commercialization terms would argue against it.
• AMT/CCI: Do not chase the premarket rally on reported discussions alone. Put both on an event watchlist and seek evidence of signed leases, deployment schedule, and incremental economics; reversal of the move without confirmation is a near-term risk.
• Risk checks: For MRNA, monitor detailed efficacy and safety data and subsequent guidance. For AMT/CCI, monitor company confirmation and lease terms. If neither catalyst produces verifiable economics, treat the respective price moves as sentiment-driven rather than a durable earnings revision.